Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

South China Morning Post - Nov 13, 2026

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...

Read full article

More News

Still Surge

Let your "surge" of emotions burst forth when reading the news articles acknowledging the beauty and vastness of Science and futuristic Technologies.

NEWSLETTER